|Articles|October 1, 2015
INC Research Receives iCardiac Site Certification
Advertisement
INC Research announced it is now certified to use the iCardiac Early Precision QT approach for evaluating the cardiac safety of new compounds in Phase I clinical development. INC’s use of iCardiac Early Precision QT technology in place, INC may be able to eliminate the need for a separate, dedicated Thorough QT (TQT) study, which can cost between $2 million and $5 million for its clients.
Read
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Praxis Reports Positive Phase III Results for Ulixacaltamide in Essential Tremor
2
Setting the Limits of Autonomy with Autonomous Agents for Clinical Research
3
Eli Lilly’s Orforglipron Shows Superior Efficacy Across Multiple Phase III Trials in Type 2 Diabetes
4
Adaptive Trial Design as a Pathway to Faster Development
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
